|
Market Closed -
NSE India S.E.
04:35:10 04/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,899.00 INR | -0.89% |
|
-0.75% | +10.43% |
| 01/09 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 01/09 | Trump announces new round of drug-pricing deals | RE |
| Market Cap | 4,55600Cr 4.82TCr 4.15TCr 3.9TCr 3.57TCr 6.68TCr 6.7TCr 46TCr 18TCr 2,33600Cr 18TCr 18TCr 7,53700Cr | P/E 2027 * |
35x | P/E 2028 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,28600Cr 4.54TCr 3.91TCr 3.67TCr 3.36TCr 6.28TCr 6.3TCr 43TCr 17TCr 2,19700Cr 17TCr 17TCr 7,08900Cr | EV / Sales 2027 * |
6.58x | EV / Sales 2028 * | 5.79x |
| Free-Float |
44.39% | Yield 2027 * |
0.9% | Yield 2028 * | 1.05% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -0.89% | ||
| 1 week | -0.75% | ||
| Current month | -4.32% | ||
| 1 month | -3.28% | ||
| 3 months | +6.18% | ||
| 6 months | +8.36% | ||
| Current year | +10.43% |
| 1 week | 1,895 |  | 1,984.8 |
| 1 month | 1,868.3 | | 1,984.8 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.89% | -0.75% | +20.29% | +71.24% | 4.86TCr | |
| -1.72% | -1.23% | +50.07% | +117.58% | 4.13TCr | |
| -2.01% | -5.82% | +11.09% | +82.43% | 1.21TCr | |
| -0.70% | -2.46% | -12.25% | +11.21% | 1.19TCr | |
| +0.57% | -0.56% | +26.56% | +153.11% | 914.92Cr | |
| +0.08% | -4.04% | +24.10% | +43.00% | 748.61Cr | |
| -0.89% | -0.93% | +21.59% | +221.93% | 734.08Cr | |
| -1.67% | -0.31% | +41.90% | -11.56% | 752.04Cr | |
| -0.16% | -2.87% | -42.37% | +14.21% | 519.04Cr | |
| -1.60% | -2.22% | +35.48% | +101.64% | 465.36Cr | |
| Average | -0.90% | -0.90% | +17.65% | +80.48% | 1.55TCr | |
| Weighted average by Cap. | -1.09% | -0.41% | +25.03% | +85.42% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 65TCr 689.03Cr 593.33Cr 557.46Cr 510Cr 953.86Cr 956.73Cr 6.59TCr 2.56TCr 33TCr 2.59TCr 2.53TCr 1,07700Cr | 73TCr 771.6Cr 664.43Cr 624.26Cr 571.11Cr 1.07TCr 1.07TCr 7.38TCr 2.87TCr 37TCr 2.9TCr 2.83TCr 1,20600Cr |
| Net income | 13TCr 137.24Cr 118.18Cr 111.03Cr 101.58Cr 189.98Cr 190.55Cr 1.31TCr 509.76Cr 6.65TCr 515.27Cr 504.07Cr 21TCr | 15TCr 162.62Cr 140.03Cr 131.56Cr 120.36Cr 225.12Cr 225.79Cr 1.56TCr 604.03Cr 7.88TCr 610.56Cr 597.29Cr 25TCr |
| Net Debt | -27TCr -286.47Cr -246.68Cr -231.77Cr -212.04Cr -396.58Cr -397.77Cr -2.74TCr -1.06TCr -14TCr -1.08TCr -1.05TCr -45TCr | -34TCr -358.18Cr -308.43Cr -289.79Cr -265.12Cr -495.85Cr -497.34Cr -3.43TCr -1.33TCr -17TCr -1.34TCr -1.32TCr -56TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | ₹1,899.00 | -0.89% | 7,61,333 |
| 03/26/03 | ₹1,916.00 | -0.81% | 12,05,188 |
| 02/26/02 | ₹1,931.70 | +0.14% | 12,45,419 |
| 01/26/01 | ₹1,929.00 | -2.81% | 35,95,272 |
| 31/26/31 | ₹1,984.80 | +3.37% | 24,13,221 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
